Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Frankfurt - Delayed Quote EUR

DanCann Pharma A/S (DAN0.F)

Compare
0.3660
+0.0412
+(12.68%)
At close: February 28 at 3:29:01 PM GMT+1
Currency in DKK All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
8,000
6,352
5,749
874
--
Cost of Revenue
9,141
9,795
11,419
7,368
2,835
Gross Profit
-1,141
-3,443
-5,670
-6,494
-2,835
Operating Expense
11,210
12,831
10,748
8,014
3,036
Operating Income
-12,351
-16,274
-16,418
-14,508
-5,871
Net Non Operating Interest Income Expense
-2,184
-2,124
-1,832
-677
-116
Pretax Income
-58,381
-62,239
-18,250
-15,185
-5,987
Tax Provision
730
21
-2,186
-3,435
-1,732
Net Income Common Stockholders
-59,111
-62,260
-16,064
-11,750
-4,255
Diluted NI Available to Com Stockholders
-59,111
-62,260
-16,064
-11,750
-4,255
Basic EPS
-0.10
-0.13
-0.07
-0.11
-0.21
Diluted EPS
-0.10
-0.13
-0.07
-0.11
-0.21
Basic Average Shares
1,541,096.3500
493,413.5380
226,502.6130
105,714.6520
20,730.7700
Diluted Average Shares
1,541,096.3500
493,413.5380
226,502.6130
105,714.6520
20,730.7700
Total Operating Income as Reported
-56,192
-60,115
-16,418
-14,508
-5,871
Total Expenses
20,351
22,626
22,167
15,382
5,871
Net Income from Continuing & Discontinued Operation
-59,111
-62,260
-16,064
-11,750
-4,255
Normalized Income
-24,915.0200
-28,064.0200
-16,064
-11,750
-4,255
Interest Income
-114
204
1,191
578
24
Interest Expense
2,070
2,328
3,023
1,255
140
Net Interest Income
-2,184
-2,124
-1,832
-677
-116
EBIT
-56,311
-59,911
-15,227
-13,930
-5,847
EBITDA
-9,206
-12,690
-12,996
-13,040
-5,753
Reconciled Cost of Revenue
9,141
9,795
11,419
7,368
2,835
Reconciled Depreciation
47,105
47,221
2,231
890
94
Net Income from Continuing Operation Net Minority Interest
-59,111
-62,260
-16,064
-11,750
-4,255
Total Unusual Items Excluding Goodwill
-43,841
-43,841
--
--
--
Total Unusual Items
-43,841
-43,841
--
--
--
Normalized EBITDA
34,635
31,151
-12,996
-13,040
-5,753
Tax Rate for Calcs
0.0002
0.0002
0.0001
0.0002
0.0003
Tax Effect of Unusual Items
-9,645.0200
-9,645.0200
--
--
--
12/31/2020 - 5/6/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

EVT.BE Evotec SE
8.27
-0.66%
 
EVT.VI Evotec SE
8.23
-3.58%
 
TKD.SG Takeda Pharmaceutical Co Ltd
27.50
+1.55%
 
N4P.L N4 Pharma Plc
0.5250
0.00%
 
TKUN.TA Tikun Olam-Cannbit Pharmaceuticals Ltd
35.30
-6.12%
 
PLCN.CN Cannibble Food-Tech Ltd.
0.0200
0.00%
 
SBX.DE SynBiotic SE
3.6500
+1.11%
 
INCR.TA InterCure Ltd.
560.00
-1.69%
 
DICOT.ST Dicot Pharma AB
0.2745
-4.85%
 
MYCO.CN Mydecine Innovations Group Inc.
0.0050
0.00%